Settembre 2021 - Nouscom

Nouscom announces initial results from Phase 1 trial for NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine, in MSI-H solid tumors

Results presented at the European Society of Medical Oncology (ESMO) congress BASEL, Switzerland – 16th September 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

Nouscom AG: Poster on initial results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at ESMO

Our abstract “Initial Results from a Phase I Study of NOUS-209, an Off-the-Shelf Viral Vectored Immunotherapy Encoding 209 Shared Frame Shift Peptide Neoantigens, with Pembrolizumab, for the [...]

error: Content is protected !!!